A One Year, Open-label, Study to Evaluate the Safety and Tolerability of Risperidone Implants as a Maintenance Treatment in Patients With Schizophrenia

Trial Profile

A One Year, Open-label, Study to Evaluate the Safety and Tolerability of Risperidone Implants as a Maintenance Treatment in Patients With Schizophrenia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Braeburn Pharmaceuticals
  • Most Recent Events

    • 26 Apr 2017 Results from this trial are expected later in 2017, according to a Braeburn Pharmaceuticals media release.
    • 07 Oct 2016 Planned number of patients changed from 100 to 145.
    • 07 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top